KEYTRUDA QLEX Approved in Japan for Subcutaneous Use Across All KEYTRUDA Indications
Japan's Ministry of Health, Labour and Welfare has approved KEYTRUDA QLEX for subcutaneous administration across all KEYTRUDA indications already approved in Japan. The September 2026 decision gives Merck's pembrolizumab franchise an additional administration route, combining pembrolizumab with berahyaluronidase alfa to support delivery under the skin.
For pharmaceutical procurement teams, the development extends beyond oncology treatment. A new administration format can influence demand planning, healthcare delivery models, packaging requirements and the wider supply chain supporting specialty medicines.
What Is KEYTRUDA QLEX?
KEYTRUDA QLEX combines pembrolizumab, an anti-PD-1 therapy, with berahyaluronidase alfa. The latter helps enhance dispersion and permeability, allowing pembrolizumab to move through tissue following subcutaneous administration.
The Japanese product is planned to use the KEYJECT trademark for its subcutaneous injection. Healthcare providers can administer the formulation in the thigh or abdomen, avoiding the area around the navel.
The formulation offers two administration schedules:
A 2.4 mL dose administered over approximately one minute every three weeks.
A 4.8 mL dose administered over approximately two minutes every six weeks.
This creates an alternative to conventional intravenous administration while keeping pembrolizumab at the center of the treatment approach.
Japan Approval Expands the Reach of Subcutaneous Pembrolizumab
The Japanese approval covers all indications approved in Japan for KEYTRUDA. That broad regulatory scope distinguishes the decision from approvals that apply only to selected cancer types or specific treatment settings.
Merck says the approval represents the first and only subcutaneous immune checkpoint inhibitor in Japan that a healthcare provider can administer in as little as one minute. The company also highlights the availability of two dosing options and greater flexibility around treatment settings.
The approval follows a broader international expansion of the subcutaneous formulation. The U.S. FDA approved KEYTRUDA QLEX in September 2025 across most solid tumor indications at the time, while the European Commission approved subcutaneous pembrolizumab across all 33 adult KEYTRUDA indications approved in the European Union in November 2025.
Clinical Evidence Behind the Japanese Decision
The Japanese approval rests on data from the Phase 3 MK-3475A-D77 trial. The study compared subcutaneous KEYTRUDA QLEX with intravenous KEYTRUDA every six weeks in patients with treatment-naïve metastatic non-small cell lung cancer who had no EGFR, ALK or ROS1 genomic tumor aberrations.
The trial demonstrated comparable pharmacokinetic exposure between the two formulations. Merck also reported consistent overall response rates in descriptive analyses, with 45% in the KEYTRUDA QLEX arm and 42% in the KEYTRUDA arm when both were administered with chemotherapy.
The company reported no notable differences in progression-free survival or overall survival between the groups. These findings provided the clinical foundation for the Japanese regulatory decision.
What the Approval Means for Pharmaceutical Procurement
A broad indication approval can affect procurement planning because healthcare providers may increasingly require the subcutaneous formulation across multiple oncology treatment pathways.
Procurement teams should pay attention to several operational factors:
Demand forecasting: Wider eligibility can increase the potential number of treatment settings in which the subcutaneous formulation enters purchasing plans.
Inventory planning: Buyers may need to account for product-specific presentations, dosing schedules and storage requirements when planning inventory.
Healthcare setting requirements: Shorter administration times could support use across different care environments, potentially changing purchasing patterns among hospitals and oncology centers.
Supplier coordination: Specialty pharmaceutical supply chains require reliable coordination between manufacturers, distributors, healthcare institutions and other authorized participants.
Regulatory documentation: Buyers operating across borders need accurate product, regulatory and import documentation that corresponds with the destination market.
The Japanese approval therefore has relevance for procurement professionals even though KEYTRUDA QLEX itself is a finished pharmaceutical product rather than a conventional industrial chemical.
Supply Chain Considerations for Subcutaneous Oncology Medicines
The transition from an intravenous presentation to a subcutaneous formulation involves more than changing the route of administration. Manufacturers must maintain consistency in formulation, packaging, quality controls and distribution throughout the supply chain.
For buyers, quality and traceability remain central requirements. Specialty oncology products require controlled handling and documentation, making supplier qualification an important part of procurement decisions.
The introduction of berahyaluronidase alfa also creates an additional component in the product's manufacturing and supply chain profile. Merck identifies berahyaluronidase alfa as a variant of hyaluronidase developed and manufactured by Alteogen Inc.
As subcutaneous formulations become more established, procurement teams may increasingly assess not only the active pharmaceutical ingredient but also formulation components, manufacturing capacity and supply continuity.
How Faster Administration Could Affect Healthcare Operations
KEYTRUDA QLEX can be administered by a healthcare provider in approximately one minute on the three-week schedule or approximately two minutes on the six-week schedule.
That shorter administration time may have operational implications for oncology facilities. A treatment that requires less administration time can potentially affect appointment scheduling, chair utilization and staff workflow, although the actual impact will vary between healthcare settings.
The availability of two dosing intervals also gives healthcare providers additional scheduling flexibility. For procurement departments, this can make demand patterns more closely connected to treatment protocols and patient scheduling.
The broader strategic point is that pharmaceutical innovation increasingly involves delivery technology alongside therapeutic innovation. A medicine's route and speed of administration can influence how healthcare organizations plan capacity and manage resources.
KEYTRUDA QLEX and the Global Oncology Market
KEYTRUDA remains a major component of Merck's oncology portfolio, and the company continues to study pembrolizumab across a wide range of cancers and treatment settings. Merck reports more than 2,800 clinical trials involving KEYTRUDA across different cancers and treatment settings.
The regulatory expansion of the subcutaneous formulation adds another dimension to that established franchise. Japan now joins the United States and European Union among major markets where subcutaneous pembrolizumab has received regulatory approval.
Merck's 2026 reporting also identifies several additional KEYTRUDA QLEX regulatory developments, including approvals and label changes involving ovarian cancer, renal cell carcinoma, bladder cancer and triple-negative breast cancer.
For international procurement organizations, broader regulatory acceptance can simplify long-term planning around subcutaneous oncology products, although market-specific authorization, labeling and import requirements still apply.
What Buyers Should Monitor Next
The Japanese approval creates a useful signal for procurement teams tracking the evolution of specialty pharmaceutical delivery formats. Buyers should monitor several developments as the product moves further into commercial use.
First, watch adoption patterns. Regulatory approval establishes availability but does not automatically determine how quickly hospitals and treatment centers shift toward a new formulation.
Second, track supply continuity. Subcutaneous products may require different production, packaging and distribution planning than established intravenous presentations.
Third, follow regulatory expansion. Additional approvals or label changes can alter the addressable treatment population and consequently affect demand expectations.
Fourth, maintain supplier verification. Pharmaceutical procurement requires careful review of manufacturer credentials, regulatory status, product specifications and applicable import requirements.
For chemical and pharmaceutical trading companies, the broader lesson is clear: developments in drug delivery can create new procurement requirements even when the underlying therapy remains familiar.
The Bottom Line for Procurement Teams
Japan's approval of KEYTRUDA QLEX expands the availability of subcutaneous pembrolizumab across all KEYTRUDA indications approved in the country. The formulation combines pembrolizumab with berahyaluronidase alfa and offers healthcare providers administration options measured in minutes rather than the longer process associated with intravenous delivery.
For procurement professionals, the development highlights the growing importance of formulation technology, regulatory coverage and supply chain readiness in specialty medicines. As subcutaneous oncology treatments gain broader regulatory acceptance, buyers will need to monitor demand, product specifications, supplier reliability and market-specific requirements.
Refined Glycerine 99.7% Min USP BP
Found this useful?
